Atherosclerosis
Volume 212, Issue 2 , Pages 457-465 , October 2010

Immune responses against aldehyde-modified laminin accelerate atherosclerosis in Apoe−/− mice

  • Pontus Dunér

      Affiliations

    • Department of Clinical Sciences, Malmö University Hospital, Lund University, Lund, Sweden
    • ,
  • Fong To

      Affiliations

    • Department of Clinical Sciences, Malmö University Hospital, Lund University, Lund, Sweden
    • ,
  • Katarina Berg

      Affiliations

    • Department of Clinical Sciences, Malmö University Hospital, Lund University, Lund, Sweden
    • ,
  • Ragnar Alm

      Affiliations

    • Department of Clinical Sciences, Malmö University Hospital, Lund University, Lund, Sweden
    • ,
  • Harry Björkbacka

      Affiliations

    • Department of Clinical Sciences, Malmö University Hospital, Lund University, Lund, Sweden
    • ,
  • Daniel Engelbertsen

      Affiliations

    • Department of Clinical Sciences, Malmö University Hospital, Lund University, Lund, Sweden
    • ,
  • Gunilla Nordin Fredrikson

      Affiliations

    • Department of Clinical Sciences, Malmö University Hospital, Lund University, Lund, Sweden
    • Faculty of Health and Society, Malmö University, Malmö, Sweden
    • ,
  • Jan Nilsson

      Affiliations

    • Department of Clinical Sciences, Malmö University Hospital, Lund University, Lund, Sweden
    • Corresponding Author InformationCorresponding author at: CRC, Entrance 72, Building 60:13, Malmö University Hospital, S-205 02 Malmö, Sweden. Tel.: +46 40391230, fax: +46 40391212.
    • ,
  • Eva Bengtsson

      Affiliations

    • Department of Clinical Sciences, Malmö University Hospital, Lund University, Lund, Sweden

Received 27 November 2009 ,Revised 13 July 2010 ,Accepted 15 July 2010.

References 

  1. Steinberg D, Lewis A. Oxidative modification of LDL and atherogenesis. Circulation. 1997;95:1062–1071
  2. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med. 2000;247:371–380
  3. Frostegård J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T cell activation by oxidized low density lipoprotein. Arterioscler Thromb. 1992;12:461–467
  4. Fredrikson GN, Hedblad B, Berglund G, et al. Identification of immune responses against aldehyde-modified peptide sequences in apo B-100 associated with cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003;23:872–878
  5. Hulthe J, Bokemark L, Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol. 2001;21:101–107
  6. Greilberger J, Schmut O, Jurgens G. In vitro interactions of oxidatively modified LDL with type I, II, III, IV, and V collagen, laminin, fibronectin, and poly-d-lysine. Arterioscler Thromb Vasc Biol. 1997;17:2721–2728
  7. Duner P, To F, Alm R, et al. Immune responses against fibronectin modified by lipoprotein oxidation and their association with cardiovascular disease. J Intern Med. 2009;265:593–603
  8. Timpl R. Structure and biological activity of basement membrane proteins. Eur J Biochem. 1989;180:487–502
  9. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med. 2000;17:299–307
  10. Fredrikson GN, Soderberg I, Lindholm M, et al. Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscler Thromb Vasc Biol. 2003;23:879–884
  11. Khallou-Laschet J, Tupin E, Caligiuri G, et al. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. Atherosclerosis. 2006;184:330–341
  12. Wigren M, Bengtsson D, Duner P, et al. Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ Res. 2009;104:e62–70
  13. Fredrikson GN, Schiopu A, Berglund G, Alm R, Shah PK, Nilsson J. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis. 2007;194:e188–192
  14. Sjogren P, Fredrikson GN, Samnegard A, et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J. 2008;29:2218–2226
  15. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003;21:3–12
  16. Turk Z, Ljubic S, Turk N, Benko B. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta. 2001;303:105–115
  17. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA. 1995;92:821–825
  18. Fredrikson GN, Andersson L, Soderberg I, et al. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity. 2005;38:171–179
  19. Schiopu A, Bengtsson J, Soderberg I, et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation. 2004;110:2047–2052
  20. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12:178–180
  21. Mor A, Planer D, Luboshits G, et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:893–900
  22. Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127:89–97
  23. van Es T, van Puijvelde GH, Ramos OH, et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun. 2009;388:261–265
  24. Chen S, Crother TR, Arditi M. Emerging role of IL-17 in atherosclerosis. J Innate Immun. 2010;2:325–333
  25. Taleb S, Romain M, Ramkhelawon B, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med. 2009;206:2067–2077
  26. Upadhya S, Mooteri S, Peckham N, Pai RG. Atherogenic effect of interleukin-2 and antiatherogenic effect of interleukin-2 antibody in apo-E-deficient mice. Angiology. 2004;55:289–294
  27. Sukovich DA, Kauser K, Shirley FD, DelVecchio V, Halks-Miller M, Rubanyi GM. Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17beta-estradiol. Arterioscler Thromb Vasc Biol. 1998;18:1498–1505
  28. Schieffer B, Selle T, Hilfiker A, et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004;110:3493–3500
  29. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517
  30. Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control?. J Intern Med. 2008;263:464–478

PII: S0021-9150(10)00556-3

doi: 10.1016/j.atherosclerosis.2010.07.014

Atherosclerosis
Volume 212, Issue 2 , Pages 457-465 , October 2010

Article Tools

* Image Usage & Resolution